Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207337 | 0.85 | NFE2L2 (0.35) | NFE2L2 | |
| SCHEMBL3466127 | 0.83 | CA12 (0.36) | NFE2L2 | |
| SCHEMBL27827263 | 0.81 | NFE2L2 (0.34) | NFE2L2 | |
| SCHEMBL27827222 | 0.79 | NFE2L2 (0.33) | NFE2L2SYK | |
| SCHEMBL3126398 | 0.79 | PIK3C3 (0.34) | NFE2L2PIK3CBSYK | |
| SCHEMBL3465609 | 0.79 | NFE2L2 (0.33) | NFE2L2 | |
| SCHEMBL10920036 | 0.78 | ROCK1 (0.40) | ROCK1 | |
| SCHEMBL27827248 | 0.78 | NFE2L2 (0.32) | NFE2L2 | |
| SCHEMBL27845941 | 0.78 | NFE2L2 (0.32) | NFE2L2 | |
| SCHEMBL3465567 | 0.74 | ALDH1A1 (0.32) | NFE2L2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| CN-102227425-A | Azaindazole compounds as ccr1 receptor antagonists | BOEHRINGER INGELHEIM INT | 2011-10-26 | — | — | CN | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | NFE2L2 3394/4885ROCK1 2503/4885PIK3CD 4069/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | NFE2L2 832/4885ROCK1 2680/4885PIK3CD 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.